Cellectis Q3 2023 Adj EPS $(0.36) Beats $(0.42) Estimate, Sales $1.64M Miss $3.58M Estimate
Portfolio Pulse from vinayak@benzinga.com
Cellectis reported Q3 2023 adjusted EPS of $(0.36), beating the estimate of $(0.42) by 14.29%. However, the company's sales of $1.64M missed the estimate of $3.58M by 54.08%. This represents a 37.93% increase in EPS and a 14.42% decrease in sales compared to the same period last year.
November 06, 2023 | 10:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cellectis' Q3 2023 results showed a better than expected EPS but lower than expected sales. This mixed result could lead to uncertainty in the market.
Cellectis' EPS beat estimates, which is a positive signal for investors. However, the company's sales missed estimates, which could be a concern. The mixed results could lead to uncertainty in the market, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100